MGRX

Mangoceuticals, Inc.

$0.19

-3.96%
SectorHealthcareIndustryHealth Information ServicesCountryUnited States

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Source: Yahoo Finance
Q-Score22/ 100
Market Cap$4.2M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.93
AI summary

Price & performance

1M-45.5%
3M-20.6%
YTD-72.6%
1Y-88.6%
52-week range—
Beta0.93
Full chart and returns against a benchmark

Q-Score

22/ 100

Quality against peers; 50 is the peer median.

Growth22
Risk26
Performance39
Valuation25
Profitability33
Leverage24
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$456K-26.0%
Net income-$20.6M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtApr 1, 2026
Late filing noticeMay 15, 2026
Exchange listing noticeFeb 6, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

MGRXIndustryP/E—67.40P/S13.344.25EV/EBITDA—44.97P/B0.346.14PEG—0.25
Dividend yield0.00%
Every valuation metric